{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T05:54:46Z","timestamp":1671602086498},"reference-count":29,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2010,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1111\/j.1365-2354.2009.01134.x","type":"journal-article","created":{"date-parts":[[2009,8,21]],"date-time":"2009-08-21T02:59:26Z","timestamp":1250823566000},"page":"167-171","source":"Crossref","is-referenced-by-count":0,"title":["KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?"],"prefix":"10.1155","volume":"19","author":[{"given":"M.","family":"HEBBAR","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"FOURNIER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"ROMANO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","reference":[{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB1","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/01.sla.0000141198.92114.f6","article-title":"Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival","volume":"240","author":"Adam","year":"2004","journal-title":"Annals of Surgery"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB2","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB3","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/jco.2008.26.15_suppl.4000","article-title":"KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience","volume":"26","author":"Bokemeyer","year":"2008","journal-title":"ASCO congress. Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB4","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1200\/jco.2007.25.18_suppl.4069","article-title":"Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): preliminary results","volume":"25","author":"Bouch\u00e9","year":"2007","journal-title":"ASCO congress. Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB5","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2005.08.037","article-title":"Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry","volume":"23","author":"Chung","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB6","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/jco.2008.26.15_suppl.4127","article-title":"Panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): effect of KRAS mutation status on second-line treatment (tx) with pmab and FOLFIRI","volume":"26","author":"Cohn","year":"2008","journal-title":"ASCO congress. Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"1351","author":"Cunningham","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB8","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6603685","article-title":"Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy","volume":"96","author":"Di Fior\u00e9","year":"2007","journal-title":"British Journal of Cancer"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB9","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/jco.2008.26.15_suppl.4035","article-title":"Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: analysis of 281 individual data from published series","volume":"26","author":"Di Fior\u00e9","year":"2008","journal-title":"ASCO congress. Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000138352","article-title":"High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?","volume":"74","author":"Ducreux","year":"2008","journal-title":"Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00280-006-0372-9","article-title":"Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer","volume":"60","author":"Duffour","year":"2007","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/01.cad.0000217425.44584.9f","article-title":"Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer","volume":"17","author":"Hebbar","year":"2006","journal-title":"Anti-Cancer Drugs"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000127385","article-title":"Assessment of easily available predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer","volume":"73","author":"Hebbar","year":"2007","journal-title":"Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB14","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"The New England Journal of Medicine"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB15","unstructured":"Karapetis C. , Khambata-Ford S. , Jonker D. , O\u2019Callaghan C. , Tu D. , Tebbutt N. , Simes J. , Langer C. , Moore M. & Zalcberg J.O. (2008) KRAS mutation status is a predictive biomarker for cetuximab benefit in the treatment of advanced colorectal cancer - results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. 10th World Congress on Gastrointestinal Cancer. Abstr 0.037."},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(07)61086-1","article-title":"Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial","volume":"370","author":"Koopman","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB17","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1200\/JCO.2006.06.7595","article-title":"Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines","volume":"24","author":"Lenz","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB18","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","article-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"Li\u00e8vre","year":"2006","journal-title":"Cancer Research"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","article-title":"KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab","volume":"26","author":"Li\u00e8vre","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB20","first-page":"994","article-title":"Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts","volume":"8","author":"Prewett","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB21","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/jco.2008.26.15_suppl.4075","article-title":"Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (METHEP)","volume":"26","author":"Rivoire","year":"2008","journal-title":"ASCO congress. Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","article-title":"Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial","volume":"370","author":"Seymour","year":"2007","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB23","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","article-title":"EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer","volume":"26","author":"Sobrero","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB27","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/jco.2007.25.18_suppl.4000","article-title":"Randomized phase III study of irinotecan and 5-FU\/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"ASCO congress. Journal of Clinical Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1200\/jco.2008.26.15_suppl.2","article-title":"KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: the CRYSTAL experience","volume":"26","author":"Van Cutsem","year":"2008","journal-title":"ASCO congress. Journal of Clinical Oncology"},{"issue":"Suppl 6","key":"10.1111\/j.1365-2354.2009.01134.x-BIB26","first-page":"710","article-title":"KRAS status and efficacy in the CRYSTAL study: first-line treatment of patients with metastatic colorectal cancer receiving FOLFIRI with or without cetuximab","volume":"19","author":"Van Cutsem","year":"2008","journal-title":"European Society of Medical Oncology Meeting. Annals of Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB28","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/annonc\/mdf337","article-title":"Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity","volume":"13","author":"Xu","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1111\/j.1365-2354.2009.01134.x-BIB29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00280-002-0506-7","article-title":"High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer","volume":"50","author":"Ychou","year":"2002","journal-title":"Cancer Chemotherapy and Pharmacology"}],"container-title":["European Journal of Cancer Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2354.2009.01134.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2354.2009.01134.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:09:51Z","timestamp":1671541791000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2354.2009.01134.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2354.2009.01134.x","relation":{},"ISSN":["0961-5423","1365-2354"],"issn-type":[{"value":"0961-5423","type":"print"},{"value":"1365-2354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}